F-star Therapeutics (FSTX) Stock Price, News & Analysis

Company Overview

F-star Therapeutics, Inc. is a clinical-stage immuno-oncology company. It focuses on transforming the lives of patients with cancer through the development of tetravalent mAb2 bispecific antibodies. The firm's product candidate, FS118, simultaneously targets two immune checkpoint receptors, LAG-3 and PD-L1, to directly address known tumor evasion pathways. The company was founded on October 7, 2002 and is headquartered in Cambridge, the United Kingdom.

Key Stats

• Today's Range: $7.12 to $7.12
• 50-Day Range: $4.42 to $7.12
• 52-Week Range: $2.07 to $7.12
• Volume: N/A
• Average Volume: 709,213 shs
• Market Capitalization: $156.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

FSTX Stock Analysis - Frequently Asked Questions

How were F-star Therapeutics' earnings last quarter?

F-star Therapeutics, Inc. (NASDAQ:FSTX) announced its earnings results on Wednesday, November, 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.58) by $0.06. The business had revenue of $0.75 million for the quarter, compared to analysts' expectations of $7.18 million.

What other stocks do shareholders of F-star Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that F-star Therapeutics investors own include New Age Brands (NF), Aurora Cannabis (ACB), Trican Well Service (TCW), Meta Platforms (META), NIO (NIO), Plug Power (PLUG) and Copper Mountain Mining (CMMC).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 2/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:FSTX
• CUSIP: N/A
• CIK: 1566373
• Web: www.f-star.com
• Phone: 441223497400
• Fax: 508-381-0347
• Employees: 84
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-31,280,000.00
• Net Margins: N/A
• Pretax Margin: -213.97%
• Return on Equity: -57.08%
• Return on Assets: -42.40%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 3.38
• Quick Ratio: 3.38

Sales & Book Value

• Annual Sales: $21.17 million
• Price / Sales: 7.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.70 per share
• Price / Book: 1.51

Miscellaneous

• Outstanding Shares: 21,980,000
• Free Float: 21,279,000
• Market Cap: $156.50 million
• Optionable: Not Optionable
• Beta: 0.85